NU 670 Unit 4 adverse effect derivation record example

Deriving Olanzapine's Adverse Effects From Where It Binds: Six Receptors, Their Predicted Effects, and What the Trials Found

Student Name

Department of Nursing, Herzing University

NU 670: Advanced Psychopharmacology and Health Promotion

Instructor Name

February 11, 2026

Deriving Olanzapine's Adverse Effects From Where It Binds: Six Receptors, Their Predicted Effects, and What the Trials Found

The Binding Profile

Olanzapine is a second-generation antipsychotic with a broad receptor profile. It binds with high affinity to histamine H1 receptors, serotonin 5-HT2A and 5-HT2C receptors, and muscarinic acetylcholine receptors; with somewhat lower affinity to dopamine D2 receptors; and with moderate affinity to alpha-1 adrenergic receptors (Stahl, 2021). At usual doses, its therapeutic effect is attributed mainly to D2 antagonism in the mesolimbic pathway, modified by 5-HT2A antagonism. Every other binding site is a source of effects that were not the purpose of the drug. The record below reasons from each site to the effects it predicts, then compares the predictions with what clinical trials and practice have found.

Derivation, Receptor by Receptor

The table summarizes each binding site, the effect predicted from it, and how strongly the prediction is supported.

The Metabolic Effects: Prediction and Beyond

The receptor profile predicts weight gain through the combined effect of H1 and 5-HT2C blockade on appetite, and weight gain in turn predicts insulin resistance and dyslipidemia. That prediction is borne out strongly. In the large effectiveness trial of antipsychotics in chronic schizophrenia, olanzapine was associated with greater weight gain and greater increases in glycated hemoglobin, cholesterol, and triglycerides than the other drugs studied (Lieberman et al., 2005). A later network meta-analysis of 32 antipsychotics likewise ranked olanzapine among the agents with the most weight gain (Huhn et al., 2019).

The prediction from binding only partly explains the metabolic picture. Glucose and lipid changes can appear early, sometimes before much weight is gained, which suggests effects beyond appetite. Muscarinic M3 antagonism at pancreatic beta cells, which could impair insulin secretion, has been proposed as one mechanism, but the full explanation remains uncertain. The record therefore distinguishes what the binding profile predicts confidently, weight gain through appetite, from what it only partly explains, early glucose and lipid changes.

Dose, Occupancy, and Which Effects Appear First

Binding is not all or nothing; the proportion of receptors occupied rises with dose and blood level, and different effects appear at different levels of occupancy. A positron emission tomography study in first-episode schizophrenia found that clinical response became likely when dopamine D2 occupancy exceeded about 65%, that prolactin elevation became likely above about 72%, and that extrapyramidal side effects became likely above about 78% (Kapur et al., 2000). The study used haloperidol, but the principle applies to other D2 antagonists: there is a window of occupancy in which benefit is likely and motor side effects are not.

Olanzapine's high affinity for H1 and muscarinic receptors means those receptors are substantially occupied even at low doses, well before D2 occupancy reaches the therapeutic window. That explains a common clinical observation: sedation and appetite changes appear at starting doses, before any antipsychotic benefit, while motor effects appear, if at all, only at higher doses. For Ms. R., a rise in olanzapine level after stopping smoking would therefore be expected to deepen sedation and appetite effects first, and only at considerably higher levels to add motor effects.

Comparison With Two Neighbors

The same method explains why other agents differ. Haloperidol binds D2 tightly and has little affinity for H1, muscarinic, or 5-HT2C receptors, so it causes more motor effects and prolactin elevation but little weight gain or sedation. Aripiprazole is a D2 partial agonist with modest H1 affinity, so it causes less weight gain and prolactin elevation, and its partial agonism is associated with akathisia rather than parkinsonism. None of these profiles is better in general; each trades one set of predictable effects for another, and the choice depends on which effects matter most to the person taking the drug.

What the Binding Profile Does Not Predict

Some adverse effects are not receptor effects at all and cannot be derived from the binding profile. Neuroleptic malignant syndrome, although related to dopamine blockade, is rare and idiosyncratic. Drug reaction with eosinophilia and systemic symptoms, a rare but serious hypersensitivity reaction, has been reported with olanzapine and is immune-mediated rather than receptor-mediated. Olanzapine's effect on the cardiac QT interval is small compared with some other antipsychotics. A prescriber reasoning only from binding would miss the idiosyncratic reactions, which is why the derivation is paired with the drug's actual safety record.

Predictions Relevant to Ms. R.

For the composite outpatient Ms. R., who takes olanzapine 15 mg at bedtime, the derivation explains three things she has experienced or is at risk of: her weight gain and prediabetes, from appetite effects and possibly additional metabolic effects; her daytime drowsiness when levels rose, from H1 blockade; and the risk of severe constipation, which increases when she adds diphenhydramine, another antimuscarinic and antihistamine. It also predicts that if she stopped smoking and her olanzapine levels rose, every one of these effects would intensify together, since they all come from the same drug at higher receptor occupancy.

Using the Derivation in Practice

The derivation shapes three practice habits. Monitoring follows the receptor profile: weight, glucose, lipids, blood pressure on standing, bowel habits, and prolactin-related symptoms. Counseling follows it too: patients are told that increased appetite is a drug effect, not a failure of willpower, and that constipation should be reported early. And switching decisions use it: a patient with serious metabolic effects might move to an agent with less H1 and 5-HT2C blockade, such as aripiprazole, accepting a different profile, including a higher risk of akathisia from its dopamine partial agonism.

References

Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., Arndt, T., Bäckers, L., Rothe, P., Cipriani, A., Davis, J., Salanti, G., & Leucht, S. (2019). Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis. The Lancet, 394(10202), 939-951. https://doi.org/10.1016/S0140-6736(19)31135-3

Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000). Relationship between dopamine D2 occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. American Journal of Psychiatry, 157(4), 514-520. https://doi.org/10.1176/appi.ajp.157.4.514

Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., Severe, J., & Hsiao, J. K. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353(12), 1209-1223. https://doi.org/10.1056/NEJMoa051688

Stahl, S. M. (2021). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (5th ed.). Cambridge University Press.